Stock Evaluator: Asymchem Laboratories (Tianjin) Co., Ltd. (ASLTY)
Asymchem Laboratories (Tianjin) Co., Ltd. ASLTY
$8.15
0.00
0.00%
August 7, 2026 12:11:20 PM
EST
Volume: 0
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
| DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business. The company also engages in key pharmaceutical intermediates, APIs, and formulations activities. The company was founded in 1998 and is headquartered in Tianjin, China.
Financial Summary
| Share Statistics | ASLTY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8,581.0 | $674.0 | 75% |
|
| Shares Out (Mil) | 52.3 | 43.9 | 49% |
|
| Institutional Ownership | 84.8% | 84.7% | 53% |
|
| Float (Mil) | 219.7 | 47.3 | 75% |
|
| Beta | 0.12 | 0.71 | 9% |
|
| Avg Daily Volume (000s) | 0 | 293 | 0% |
|
| Price Change (52-week) |
na | 68.8% | na |
|
| Growth | ASLTY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 14.7% | 6.8% | 72% |
|
| Net Income (5yr) | 8.0% | (1.5%) | 52% |
|
| EPS (5yr) | 6.1% | 14.9% | 40 |
|
| Dividends (5yr) | 23.1% | 0.0% | 60% |
|
| Cash Flow (5yr) | (26.8%) | (15.1%) | 23% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ASLTY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,044 | $317 | 51% |
|
| Net Income (TTM) (Mil) | $152 | ($11) | 65% |
|
| EPS (TTM) | $0.431 | ($0.700) | 52% |
|
| Operating Cash Flow (TTM) (Mil) | $225 | ($7) | 60% |
|
| Net Cash Flow (TTM) (Mil) | ($132) | $4 | 12% |
|
| Long-Term Debt (Q1) (Mil) | $37 | $6 | 37% |
|
| Enterprise Value (Q1) (Mil) | $7,945 | $575 | 70% |
|
| Valuation | ASLTY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.80 | na |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ASLTY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 40.5% | 67.5% | 51% |
|
| Net Margin | 14.6% | (1.4%) | 72% |
|
| ROA | 5.2% | (24.6%) | 72% |
|
| ROE | 6.1% | (21.4%) | 46% |
|
| Liabilities to Assets | 14.8% | 32.2% | 9% |
|
| F-Score | na | 3 | na |
|
Asymchem Laboratories (Tianjin) Co., Ltd. did not pass any screens on 9/2/2026.
